Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04770285 · ClinicalTrials.gov registry record · NA
Trial to Evaluate the Effectiveness of a Digital Therapeutics in Adults Diagnosed With Major Depressive Disorder
A NA study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- NA
- Development phase
- 386
- Enrollment target
NCT04770285: Completed NA study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT04770285 is a NA study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 386 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04770285, a NA study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- NA
- Development phase
- 386 participants
- Enrollment target
Study Summary
This study compares the effectiveness of 2 digital therapeutics in adult participants diagnosed with major depressive disorder (MDD) who are on antidepressant therapy (ADT) monotherapy for the treatment of depression.
Primary Outcome
The MADRS is used to assess depressive symptom severity. It consists of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts), each rated from 0 to 6 with zero being the "best" rating and 6 being the "worst" rating. The MADRS total score is the sum of ratings for all 10 items. The total score ranges from 0 to 60. A higher score on the MADRS represents a mo
Interventions
- DEVICE Sham
- DEVICE CT-152 - Digital Therapeutic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 386 participants |
| Start Date | 2021-02-25 |
| Est. Completion | 2022-10-26 |
| Phase | NA |
What the finished NCT04770285 record still lists
NCT04770285 is an interventional study that assigns participants to a tested intervention. The registered 386 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 2 interventions - of which Sham is the first listed.
NCT04770285 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04770285 about?
NCT04770285 is a clinical study titled "Trial to Evaluate the Effectiveness of a Digital Therapeutics in Adults Diagnosed With Major Depressive Disorder". This study compares the effectiveness of 2 digital therapeutics in adult participants diagnosed with major depressive disorder (MDD) who are on antidepressant therapy (ADT) monotherapy for the treatment of depression.
What is the current status of trial NCT04770285?
This trial is currently completed. It is a NA study. The enrollment target is 386 participants. The study started on 2021-02-25. Estimated completion is 2022-10-26.
What interventions are being tested in trial NCT04770285?
The interventions under investigation include: Sham (DEVICE), CT-152 - Digital Therapeutic (DEVICE).
Who is sponsoring clinical trial NCT04770285?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04770285's enrollment target sits among peer trials
386 271st of 2000 higher than 1,730 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645107 · 386 participants · Phase 3
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- NCT05896189 · 386 participants · NA
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
- NCT06686121 · 386 participants · Phase 3
Improving Mobility After Revascularization in Peripheral Artery Disease
- NCT07424547 · 386 participants · Phase 1
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI